Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    Self-Advocacy and Attitude: How Anna Survives (and Thrives) in Her Life with Wegener’s Granulomatosis (Pt. 3)
    Photo courtesy of Anna Smith

    Self-Advocacy and Attitude: How Anna Survives (and Thrives) in Her Life with Wegener’s Granulomatosis (Pt. 3)

    Before you read, make sure you check out Parts 1 and 2 of our interview. In Part 1, we discussed what Wegener's granulomatosis (GPA) is, Anna's diagnostic journey, and her first episode of symptoms.…

    Continue Reading Self-Advocacy and Attitude: How Anna Survives (and Thrives) in Her Life with Wegener’s Granulomatosis (Pt. 3)
    Raising Stevens-Johnson Syndrome Awareness: Viktoria’s Story (Pt. 2)
    Photo by Eyestix Studio on Unsplash: https://unsplash.com/photos/36zZoXDrGmI

    Raising Stevens-Johnson Syndrome Awareness: Viktoria’s Story (Pt. 2)

    Don't forget to read Part 1 of our interview, where we discuss what Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are, and learn more about how Viktoria ended up hospitalized. Today,…

    Continue Reading Raising Stevens-Johnson Syndrome Awareness: Viktoria’s Story (Pt. 2)
    GBS from Zika Virus Linked to Poor Olfactory Function
    ckstockphoto / Pixabay

    GBS from Zika Virus Linked to Poor Olfactory Function

    Postnatal Zika virus can cause other complications and health issues for those affected. According to Neurology Advisor, one such complication is Guillain-Barré syndrome (GBS). Researchers believe that GBS following postnatal…

    Continue Reading GBS from Zika Virus Linked to Poor Olfactory Function
    Self-Advocacy and Attitude: How Anna Survives (and Thrives) in Her Life with Wegener’s Granulomatosis (Pt. 2)
    Photo courtesy of Anna Smith

    Self-Advocacy and Attitude: How Anna Survives (and Thrives) in Her Life with Wegener’s Granulomatosis (Pt. 2)

    Before you read any further, make sure you've read Part 1 of our interview, where Anna and I discussed what Wegener's granulomatosis (GPA) is, her diagnostic journey, and how she managed her…

    Continue Reading Self-Advocacy and Attitude: How Anna Survives (and Thrives) in Her Life with Wegener’s Granulomatosis (Pt. 2)
    Raising Stevens-Johnson Syndrome Awareness: Viktoria’s Story (Pt. 1)
    Photo by Eyestix Studio on Unsplash: https://unsplash.com/photos/36zZoXDrGmI

    Raising Stevens-Johnson Syndrome Awareness: Viktoria’s Story (Pt. 1)

    Viktoria Cupay is no stranger to raising awareness about underserved and invisible illnesses. In 2016, two years after she began searching for a diagnosis, Viktoria found out that she was…

    Continue Reading Raising Stevens-Johnson Syndrome Awareness: Viktoria’s Story (Pt. 1)
    Self-Advocacy and Attitude: How Anna Survives (and Thrives) in Her Life with Granulomatosis (Pt. 1)
    Photo courtesy of Anna Smith

    Self-Advocacy and Attitude: How Anna Survives (and Thrives) in Her Life with Granulomatosis (Pt. 1)

    When Anna tells me about her diagnosis of Wegener’s granulomatosis just about thirty years ago, she shares that she does all that she can to not allow it to encompass…

    Continue Reading Self-Advocacy and Attitude: How Anna Survives (and Thrives) in Her Life with Granulomatosis (Pt. 1)

    How Quris is Aiming to Address Fragile X (and Other Rare Diseases) through Bio-AI Drug Development (Pt. 2)

    Before reading, don't forget to head to Part 1 to learn more about Quris' founder Isaac Bentwich, why Quris was developed, and how the company is using its innovative bio-AI drug development…

    Continue Reading How Quris is Aiming to Address Fragile X (and Other Rare Diseases) through Bio-AI Drug Development (Pt. 2)

    How Quris is Aiming to Address Fragile X (and Other Rare Diseases) through Bio-AI Drug Development (Pt. 1)

    Many people laud the accomplishments of clinical trials – and for, in some cases, good reason. Clinical trials have been crucial in identifying and developing therapeutic options for patients to…

    Continue Reading How Quris is Aiming to Address Fragile X (and Other Rare Diseases) through Bio-AI Drug Development (Pt. 1)

    How “Voices” Offers a New Avenue of Connection for the Chronic Illness and Rare Disease Communities

    It’s no secret that being a part of the chronic illness and/or rare disease community can sometimes be lonely and isolating. Many people, while empathetic to the challenges faced within…

    Continue Reading How “Voices” Offers a New Avenue of Connection for the Chronic Illness and Rare Disease Communities
    Pioneering RNA Therapeutics for Oncology: A Conversation with Geoff Nosrati of Nutcracker Therapeutics
    Nutcracker Therapeutics micro logo

    Pioneering RNA Therapeutics for Oncology: A Conversation with Geoff Nosrati of Nutcracker Therapeutics

    Recent advances within the medical field have prompted the development of RNA therapeutics for many different applications. These therapeutics have the potential to greatly change the treatment landscape and create…

    Continue Reading Pioneering RNA Therapeutics for Oncology: A Conversation with Geoff Nosrati of Nutcracker Therapeutics
    First Patient Dosed: BBP-671 for Propionic Acidemia
    Source: Pixabay

    First Patient Dosed: BBP-671 for Propionic Acidemia

    According to a news release from biopharmaceutical company BridgeBio Pharma, Inc., the first patient was dosed in a Phase 1 study. Researchers are evaluating the safety, tolerability, pharmacodynamics, and pharmacokinetics…

    Continue Reading First Patient Dosed: BBP-671 for Propionic Acidemia
    First Participant Dosed in IMG-004 Trial for Immunological Diseases
    source: pixabay.com

    First Participant Dosed in IMG-004 Trial for Immunological Diseases

      Near the start of August 2022, biotechnology company Inmagene Biopharmaceuticals ("Inmagene") and biopharmaceutical company HUTCHMED shared via news release that the first participant had been dosed in a Phase…

    Continue Reading First Participant Dosed in IMG-004 Trial for Immunological Diseases

    Study Data Shows Promise in LYS-SAF302 for Sanfilippo Syndrome Type A

    Both the 3rd Annual Gene Therapy for Neurological Disorders meeting and the ADVANCE 2022 Sanfilippo Community Conference were held in July 2022. During both meetings, researchers presented new data from…

    Continue Reading Study Data Shows Promise in LYS-SAF302 for Sanfilippo Syndrome Type A